Avidity Biosciences Inc. (Nasdaq: RNA), a biopharmaceutical company focused on developing RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), has announced the pricing of its upsized underwritten public offering. The company plans to sell 15,000,000 shares of its common stock at $40.00 per share, with anticipated gross proceeds of $600 million. The offering is expected to close around September 15, 2025, subject to customary closing conditions. Avidity has also provided underwriters a 30-day option to purchase an additional 2,250,000 shares. The net proceeds will be used to advance late-stage clinical programs, build commercial inventory, expand infrastructure, and support research and development. Leerink Partners, J.P. Morgan, TD Cowen, Cantor, and Wells Fargo Securities are acting as joint bookrunning managers for the offering.